Composition comprising cell and biocompatible polymer

Abstract

It is an object of the present invention to provide a cell-containing composition capable of suppressing the outflow of the cells after transplantation and improving the survival rate of the cells. The present invention provides a composition which comprises any of bone marrow stromal cell-derived neural precursor cells, bone marrow stromal cell-derived Schwann cells, or bone marrow stromal cell-derived skeletal muscle cells; and a biocompatible polymer.

What is claimed is: 
     
         1 . A method for treating nervous disease, which comprises administering to a patient suffering from nervous disease a therapeutically effective amount of a composition comprising (A) any cells of the following (a) and (b), and (B) a biocompatible polymer:
 (a) bone marrow stromal cell-derived neural precursor cells which are obtained by (1) introducing a nucleic acid comprising Notch sequences, wherein said Notch sequences consist of sequences encoding a Notch intracellular domain, and (2) culturing said bone marrow stromal cells such that said bone marrow stromal cells differentiate into neural precursor cells, wherein the resultant differentiated cells are offspring of bone marrow stromal cells into which said nucleic acid has been introduced; and   (b) bone marrow stromal cell-derived Schwann cells which are obtained by (1) collecting bone marrow stromal cells from bone marrow, and culturing said cells in a standard essential culture medium supplemented with a serum; (2) adding a reducing agent to said culture medium, and further culturing said cells; (3) adding retinoic acid to said culture medium, and further culturing said cells; and (4) adding forskolin, and/or a differentiation, survival and growth stimulating factor which acts on nerves and glial cells to said culture medium, and further culturing said cells to obtain said bone marrow stromal cell-derived Schwann cells;   wherein the biocompatible polymer is in the non-naturally occurring form of particles obtained by free-drying an aqueous solution of the biocompatible polymer followed by milling.   
     
     
         2 . The method according to  claim 1 , wherein the biocompatible polymer is a gelatin. 
     
     
         3 . The method according to  claim 1 , wherein the biocompatible polymer is a recombinant gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen. 
     
     
         4 . The method according to  claim 3 , wherein the recombinant gelatin has a repetition of a sequence characteristic for collagen represented by Gly-X-Y wherein each of X and Y independently represents any given amino acid, wherein a plurality of Gly-X-Y may be identical to or different from one another, and the recombinant gelatin has a molecular weight of 2 KDa to 100 KDa. 
     
     
         5 . The method according to  claim 3 , wherein the recombinant gelatin has a repetition of a sequence characteristic for collagen represented by Gly-X-Y wherein each of X and Y independently represents any given amino acid, wherein a plurality of Gly-X-Y may be identical to or different from one another, and the recombinant gelatin has a molecular weight of 10 KDa to 90 KDa. 
     
     
         6 . The method according to  claim 3 , wherein the recombinant gelatin has a repetition of a sequence characteristic for collagen represented by Gly-X-Y wherein each of X and Y independently represents any given amino acid, wherein a plurality of Gly-X-Y may be identical to or different from one another, and the recombinant gelatin comprises two or more sequences of cell adhesion signals in a single molecule. 
     
     
         7 . The method according to  claim 6 , wherein the cell adhesion signal has an amino acid sequence represented by Arg-Gly-Asp. 
     
     
         8 . The method according to  claim 3 , wherein the amino acid sequence of the recombinant gelatin does not comprise serine and threonine. 
     
     
         9 . The method according to  claim 3 , wherein the amino acid sequence of the recombinant gelatin does not comprise serine, threonine, asparagine, tyrosine, and cysteine. 
     
     
         10 . The method according to  claim 3 , wherein the amino acid sequence of the recombinant gelatin does not comprise an amino acid sequence represented by Asp-Arg-Gly-Asp. 
     
     
         11 . The method according to  claim 3 , wherein the recombinant gelatin is represented by the following formula:
   A-[(Gly-X-Y) n ] m -B   wherein A represents any given amino acid or amino acid sequence; B represents any given amino acid or amino acid sequence; each of an n number of X independently represents any given amino acid; each of an n number of Y independently represents any given amino acid; n represents an integer of 3 to 100; m represents an integer of 2 to 10; and further, an n number of Gly-X-Y may be identical to or different from one another.   
     
     
         12 . The method according to  claim 3 , wherein the recombinant gelatin is represented by the following formula:
   Gly-Ala-Pro-[(Gly-X-Y) 63 ] 3 -Gly   wherein each of 63 X units independently represents any given amino acid; each of 63 Y units independently represents any given amino acid; and 63 Gly-X-Y units may be identical to or different from one another.   
     
     
         13 . The method according to  claim 3 , wherein the recombinant gelatin has: (1) the amino acid sequence shown in SEQ ID NO: 1, or (2) an amino acid sequence showing a homology of 80% or more with the amino acid sequence shown in SEQ ID NO: 1 and having the property of adhering to a nerve cell or a cell capable of differentiating a nerve cell. 
     
     
         14 . The method according to  claim 3 , wherein the recombinant gelatin is crosslinked. 
     
     
         15 . The method according to  claim 3 , wherein the crosslinking is carried out with an aldehyde, a condensing agent, or an enzyme. 
     
     
         16 . The method according to  claim 1 , wherein the composition is administered locally. 
     
     
         17 . The method according to  claim 1 , wherein the composition is administered to the central nervous system of the patient. 
     
     
         18 . The method according to  claim 1 , wherein the biocompatible polymer (B) is particles of a biocompatible polymer, wherein the cells are attached on the particles. 
     
     
         19 . The method according to  claim 1 , wherein the biocompatible polymer is a non-naturally occurring recombinant gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen.